Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $43.
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $43.